93 related articles for article (PubMed ID: 14996855)
1. As targeted therapies evolve, challenges remain.
Benowitz S
J Natl Cancer Inst; 2004 Mar; 96(5):351-2. PubMed ID: 14996855
[No Abstract] [Full Text] [Related]
2. A pulse at the heart of targeted therapy.
Bradner JE
Nat Chem Biol; 2009 Mar; 5(3):144-5. PubMed ID: 19219016
[No Abstract] [Full Text] [Related]
3. A Bcr/Abl kinase antagonist for chronic myelogenous leukemia: a promising path for progress emerges.
Sausville EA
J Natl Cancer Inst; 1999 Jan; 91(2):102-3. PubMed ID: 9923844
[No Abstract] [Full Text] [Related]
4. FDA licences imatinib mesylate for CML.
Habeck M
Lancet Oncol; 2002 Jan; 3(1):6. PubMed ID: 11905608
[No Abstract] [Full Text] [Related]
5. Cancer stem cells: are we missing the target?
Jones RJ; Matsui WH; Smith BD
J Natl Cancer Inst; 2004 Apr; 96(8):583-5. PubMed ID: 15100335
[No Abstract] [Full Text] [Related]
6. Dragons 'round the fleece again: STI571 versus alpha1 acid glycoprotein.
Sausville EA
J Natl Cancer Inst; 2000 Oct; 92(20):1626-7. PubMed ID: 11036101
[No Abstract] [Full Text] [Related]
7. Reduced dose imatinib mesylate therapy for chronic myeloid leukemia.
Zipin D; Savage DG
Leuk Lymphoma; 2004 Nov; 45(11):2363-4. PubMed ID: 15512833
[No Abstract] [Full Text] [Related]
8. Imatinib mesylate.
Am J Health Syst Pharm; 2001 Dec; 58(23):2241-2. PubMed ID: 11765724
[No Abstract] [Full Text] [Related]
9. STI571 (glivec-tm): a new paradigm for the development of innovative therapies in onco-hematology?
Gambacorti C
Tumori; 2001; 87(6):S10-2. PubMed ID: 11989608
[No Abstract] [Full Text] [Related]
10. STI571: a paradigm of new agents for cancer therapeutics.
Mauro MJ; O'Dwyer M; Heinrich MC; Druker BJ
J Clin Oncol; 2002 Jan; 20(1):325-34. PubMed ID: 11773186
[TBL] [Abstract][Full Text] [Related]
11. Basic science going clinical: molecularly targeted therapy of chronic myelogenous leukemia.
Deininger MW
J Cancer Res Clin Oncol; 2004 Feb; 130(2):59-72. PubMed ID: 14605878
[TBL] [Abstract][Full Text] [Related]
12. Is red tape stifling the progress of new anticancer drugs?
Lancet Oncol; 2002 Jan; 3(1):1. PubMed ID: 11905596
[No Abstract] [Full Text] [Related]
13. Adenomatoid tumor of the testis in a patient on imatinib therapy for chronic myeloid leukemia.
Piccin A; Conneally E; Lynch M; McMenamin ME; Langabeer S; McCann S
Leuk Lymphoma; 2006 Jul; 47(7):1394-6. PubMed ID: 16923575
[No Abstract] [Full Text] [Related]
14. Bone metabolism during long-term treatment with imatinib.
O'Sullivan S; Horne A; Wattie D; Porteous F; Gamble G; Browett P; Grey A
Leuk Lymphoma; 2013 Aug; 54(8):1783-5. PubMed ID: 23278638
[No Abstract] [Full Text] [Related]
15. [Resistance mechanism of ST1571 and its prevention research--review].
Zhou X; Hou J
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2004 Oct; 12(5):713-7. PubMed ID: 15498142
[TBL] [Abstract][Full Text] [Related]
16. The clinical significance of ABCC3 as an imatinib transporter in chronic myeloid leukaemia.
Giannoudis A; Davies A; Harris RJ; Lucas CM; Pirmohamed M; Clark RE
Leukemia; 2014 Jun; 28(6):1360-3. PubMed ID: 24441286
[No Abstract] [Full Text] [Related]
17. Reduction of imatinib absorption after gastric bypass surgery.
Liu H; Artz AS
Leuk Lymphoma; 2011 Feb; 52(2):310-3. PubMed ID: 21133728
[No Abstract] [Full Text] [Related]
18. Combinations of targeted therapies take aim at multiple pathways.
Goldman B
J Natl Cancer Inst; 2003 Nov; 95(22):1656-7. PubMed ID: 14625255
[No Abstract] [Full Text] [Related]
19. Imatinib mesylate impairs Flt3L-mediated dendritic cell expansion and antitumor effects in vivo.
Taïeb J; Maruyama K; Borg C; Terme M; Zitvogel L
Blood; 2004 Mar; 103(5):1966-7; author reply 1967. PubMed ID: 14976062
[No Abstract] [Full Text] [Related]
20. Imatinib: paradigm or anomaly?
Druker BJ
Cell Cycle; 2004 Jul; 3(7):833-5. PubMed ID: 15254412
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
